Novartis considers “pay-for-performance” for CAR-T – pharmaphorum
pharmaphorum |
Novartis considers “pay-for-performance” for CAR–T
pharmaphorum Novartis is considering a “pay-for-performance” pricing scheme if its CAR–T therapy gets approved, following trial results published earlier this week. Results of the phase 2 JULIET study of 51 patients in relapsed or refractory diffuse large B-cell … CAR–T pricing decision looms large for Novartis |
